Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA023691 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA023691, RRID:AB_1846392
- Product name
- Anti-CDCA5
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CDCA5, Gene description: cell division cycle associated 5, Validated applications: WB, IHC, ICC, Uniprot ID: Q96FF9, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer
CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Kariri Y, Joseph C, Alsaleem M, Elsharawy K, Alsaeed S, Toss M, Mongan N, Green A, Rakha E
Cancers 2022;14(22):5643
Cancers 2022;14(22):5643
CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker
Shen Z, Yu X, Zheng Y, Lai X, Li J, Hong Y, Zhang H, Chen C, Su Z, Guo R
OncoTargets and Therapy 2018;Volume 11
OncoTargets and Therapy 2018;Volume 11
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Andersson E, Arvidsson Y, Swärd C, Hofving T, Wängberg B, Kristiansson E, Nilsson O
Modern Pathology 2016;29(6):616-629
Modern Pathology 2016;29(6):616-629
No comments: Submit comment
No validations: Submit validation data